Outcomes following resection of intrahepatic cholangiocarcinoma

Parissa Tabrizian, Ghalib Jibara, Jaclyn F Hechtman, Bernardo Franssen, Daniel M Labow, Myron E Schwartz, Swan N Thung, Umut Sarpel, Parissa Tabrizian, Ghalib Jibara, Jaclyn F Hechtman, Bernardo Franssen, Daniel M Labow, Myron E Schwartz, Swan N Thung, Umut Sarpel

Abstract

Objectives: The aim of this analysis was to examine prognostic features and outcomes in patients undergoing resection for intrahepatic cholangiocarcinoma (ICC).

Methods: A retrospective chart review was performed in all patients who underwent R0 or R1 resection for primary ICC between 1995 and 2011. Clinical data were abstracted and statistical analyses were conducted in the standard fashion.

Results: A total of 82 patients underwent curative hepatectomy for primary ICC; 51 patients in this cohort developed recurrence. The median follow-up of survivors was 27 months (range: 1-116 months). Recurrences were intrahepatic (65%), associated with multiple tumours (54%) and occurred during the first 2 years after hepatectomy (86%). The main factor associated with recurrence after resection was the presence of satellite lesions. Overall 5-year disease-free survival after primary resection was 16%. Factors associated with poor survival were transfusion and perineural invasion. Treatment of recurrence was undertaken in 89% of patients and repeat surgical resection was performed in 15 patients. The 3-year survival rate after recurrence was 25%. Prolonged survival after recurrence was associated with a solitary tumour recurrence.

Conclusions: Despite curative resection of ICC, recurrence can be expected to occur in 79% of patients at 5 years. Predictors of survival and recurrence after resection vary in the literature. In patients with recurrence, selection of the optimal treatment remains challenging.

© 2014 International Hepato-Pancreato-Biliary Association.

Figures

Figure 1
Figure 1
Rates of overall recurrence in patients with intrahepatic cholangiocarcinoma (ICC) after primary hepatectomy (n = 81)
Figure 2
Figure 2
Rates of overall survival in patients with intrahepatic cholangiocarcinoma (ICC) after primary hepatectomy, with recurrent and non-recurrent disease (P = 0.275) (n = 81)

References

    1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–1314.
    1. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51(Suppl. 6):1–9.
    1. Cho SY, Park SJ, Kim SH, Han SS, Kim YK, Lee KW, et al. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol. 2010;17:1823–1830.
    1. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–1357.
    1. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumours. Ann Surg. 1996;224:463–473. discussion 473–475.
    1. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248:84–96.
    1. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one year experience with 564 patients at a single institution. Ann Surg. 2007;245:755–762.
    1. Ercolani G, Vetrone G, Grazi GL, Aramaki O, Cescon M, Ravaioli M, et al. Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg. 2010;252:107–114.
    1. Cherqui D, Tantawi B, Alon R, Piedbois P, Rahmouni A, Dhumeaux D, et al. Intrahepatic cholangiocarcinoma. Results of aggressive surgical management. Arch Surg. 1995;130:1073–1078.
    1. Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Hamba H, Tanaka H, et al. Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J Surg. 2001;25:865–869.
    1. Jan YY, Yeh CN, Yeh TS, Chen TC. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol. 2005;11:1779–1784.
    1. Yeh CN, Jan YY, Chen MF. Influence of age on surgical treatment of peripheral cholangiocarcinoma. Am J Surg. 2004;187:559–563.
    1. Suzuki S, Sakaguchi T, Yokoi Y, Okamoto K, Kurachi K, Tsuchiya Y, et al. Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg. 2002;26:687–693.
    1. Lang H, Sotiropoulos GC, Frühauf NR, Dömland M, Paul A, Kind EM, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single centre experience with 27 resections in 50 patients over a 5-year period. Ann Surg. 2005;241:134–143.
    1. Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Yoshitomi H, et al. Significance of repeated resection for recurrent intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2009;56:1–5.
    1. Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K. Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg. 2012;99:1711–1717.
    1. Carrafiello G, Laganà D, Cotta E, Mangini M, Fontana F, Bandiera F, et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc Intervent Radiol. 2010;33:835–839.
    1. Kim JH, Won HJ, Shin YM, Kim PN, Lee SG, Hwang S. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol. 2011;80:e221–e225.
    1. Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17:484–491.
    1. Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113:2119–2128.
    1. Whitney R, Tatum C, Hahl M, Ellis S, Scoggins CR, McMasters K, et al. Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. J Surg Res. 2011;166:236–240.
    1. Kiefer MV, Albert M, McNally M, Robertson M, Sun W, Fraker D, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-centre study. Cancer. 2011;117:1498–1505.
    1. Sotiropoulos GC, Lang H, Broelsch CE. Surgical management of recurrent intrahepatic cholangiocellular carcinoma after liver resection. Surgery. 2005;137:669–670.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться